Gordon, A N <br/><br/>
Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  May 1997 
 - 1965-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0732-183X 
<br/><br/><label>Standard No.: </label>10.1200/JCO.1997.15.5.1965  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>CA-125 Antigen--blood<br/>Carcinoma--blood<br/>Cisplatin--administration & dosage<br/>Disease Progression<br/>Female<br/>Filgrastim<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Middle Aged<br/>Neutropenia--chemically induced<br/>Ovarian Neoplasms--blood<br/>Paclitaxel--administration & dosage<br/>Peripheral Nervous System Diseases--chemically induced<br/>Recombinant Proteins